5 studies found for:    melanoma,cancer,PARP
Show Display Options
Rank Status Study
1 Active, not recruiting An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors
Conditions: Malignant Solid Tumour;   Ovarian Cancer;   Triple Negative Breast Cancer;   Advanced Melanoma;   B-cell Malignancy, Low-grade
Interventions: Drug: E7449 alone;   Drug: E7449 plus TMZ;   Drug: E7449 plus carboplatin and paclitaxel
2 Completed A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients
Conditions: Non-hematologic Malignancies;   Metastatic Melanoma;   Breast Cancer;   Ovarian Cancer;   Primary Peritoneal Cancer;   Fallopian Tube Cancer;   Hepatocellular Carcinoma
Interventions: Drug: ABT-888;   Drug: Temozolomide
3 Completed A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine
Condition: Melanoma Neoplasms
Interventions: Drug: KU-0059436 (AZD2281)(PARP inhibitor);   Drug: dacarbazine
4 Recruiting Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Conditions: Adult Solid Neoplasm;   Bladder Carcinoma;   Breast Carcinoma;   Endometrial Carcinoma;   Esophageal Carcinoma;   Lung Carcinoma;   Malignant Head and Neck Neoplasm;   Melanoma;   Ovarian Neoplasm;   Renal Pelvis and Ureter Urothelial Carcinoma;   Testicular Lymphoma;   Ureter Carcinoma;   Urethral Carcinoma
Interventions: Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Pharmacological Study;   Drug: Veliparib
5 Terminated A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With Melanoma
Condition: Melanoma
Interventions: Drug: INO-1001;   Drug: temozolomide

Indicates status has not been verified in more than two years